Chronic AMP-kinase activation with AICAR reduces adiposity by remodeling adipocyte metabolism and increasing leptin sensitivity

Mandeep P. Gaidhu, Andrea Frontini, Steven Hung, Kathryn Pistor, Saverio Cinti, and Rolando B. Ceddia

Muscle Health Research Centre – School of Kinesiology and Health Science, York University, Toronto, ON, Canada; and Department of Molecular Pathology and Innovative Therapies, School of Medicine, University of Ancona (Politecnica delle Marche), Ancona, Italy

Abstract This study investigated the effect of chronic AMP-kinase (AMPK) activation with 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) on white adipose tissue (WAT) metabolism and the implications for visceral (VC) and subcutaneous (SC) adiposity, whole body energy homeostasis, and hypothalamic leptin sensitivity. Male Wistar rats received daily single intraperitoneal injections of either saline or AICAR (0.7 g/kg body weight) for 4 and 8 weeks and were pair-fed throughout the study. AICAR-treated rats had reduced adiposity with increased mitochondrial density in VC and SC fat pads, which was accompanied by reduced circulating leptin and time-dependent and depot-specific regulation of AMPK phosphorylation and FA oxidation. Interestingly, the anorectic effect to exogenous leptin was more pronounced in AICAR-treated animals than controls. This corresponded to reductions in hypothalamic AMPK phosphorylation and suppressor of cytokine signaling 3 content, whereas signal transducer and activator of transcription 3 phosphorylation was either unchanged or increased at 4 and 8 weeks in AICAR-treated rats. Ambulatory activity and whole-body energy expenditure (EE) were also increased with AICAR treatment. Altogether, chronic AICAR-induced AMPK activation increased WAT oxidative machinery, whole-body EE, and hypothalamic leptin sensitivity. This led to significant reductions in VC and SC adiposity without inducing energy-sparing mechanisms that oppose long-term fat loss.

Successful treatment of obesity requires a continuous reduction in adiposity and maintenance of a healthy body weight. The conventional approaches used to achieve weight loss involve exercise and diet. However, as body fat is reduced through these approaches, energy-sparing mechanisms are activated and impose a major obstacle to long-term weight loss (1). Therefore, identifying strategies to overcome these energy-sparing mechanisms is crucial to improve the outcome of weight loss programs. One potential approach would be to remodel white adipose tissue (WAT) metabolism toward a highly metabolic brown adipose tissue (BAT) phenotype that shifts metabolism toward fat oxidation instead of storage independently of altering whole-body energy expenditure (EE) through physical activity (2).

The acquisition of a “brown-like” phenotype by white adipocytes requires a substantial increase in mitochondrial content and upregulation of the oxidative machinery in these...
cells. These functional changes could ultimately reduce fat storage and adipose tissue mass. In this context, one enzyme that is central to sense the energy state of the cell and regulate ATP production through FA oxidation is AMP-kinase (AMPK). In its activated state, AMPK shuts down anabolic pathways and promotes catabolism by regulating the activity of key enzymes of intermediary metabolism (3). AMPK has also been shown to block adipocyte differentiation in the early stages by inhibiting clonal expansion, which is a critical step for adipogenesis to occur (4, 5). Additionally, treatment of preadipocytes with pharmacological agents to activate AMPK prevents the expression of late adipogenic markers, fatty acid synthase, acetyl-CoA carboxylase (ACC), and transcription factors peroxisome proliferator-activated receptor (PPAR)γ1/2 and CCAAT-enhancer-binding protein (C/EBP)α which are required for the synthesis of storage of lipids in mature adipocytes (4, 5). AMPK also phosphorylates and activates PPAR-γ coactivator-1α (PGC-1α) and promotes mitochondrial biogenesis in skeletal muscle (6).

We have recently demonstrated that prolonged (15 h) AICAR-induced AMPK activation increased mRNA expression of PPAR-γ and of its coactivator PGC-1α in isolated rat epididymal adipocytes (7). These cells also had ~4-fold higher than control expression of carnitine palmitoyl transferase-Ib, which was accompanied by a 2-fold increase in palmitate oxidation and a marked reduction in lipogenesis (7). Based on these observations, we hypothesized that chronic activation of AMPK in vivo could lead to a shift in WAT metabolism toward oxidation and lead to reduced adiposity. Additionally, the effects of chronic AMPK activation on remodeling WAT metabolism could potentially overcome the opposition to fat reduction triggered by the mechanisms. Importantly, this effect appears to be at least partially mediated by increased hypothalamic leptin sensitivity.

### MATERIALS AND METHODS

#### Reagents

FA-free BSA, free glycerol determination kit, glucose oxidase kit, isoproterenol, and palmitic acid were obtained from Sigma. [1-14C]palmitic acid was from GE Healthcare Radiochemicals (Quebec City, Quebec, Canada). Leptin was measured using an ELISA from Millipore (Billerica, MA). AICAR was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada). Recombinant rat leptin was obtained from Dr. A. F. Parlow at the National Hormone and Peptide Program (Torrance, CA). All antibodies were from Cell Signaling Technology Inc. (Beverly, MA) unless noted otherwise. Phospho-acetyl-CoA carboxylase was obtained from Upstate (Charlottesville, VA), and uncoupling protein 1 (UCP-1) was from Abcam (Cambridge, MA). All other chemicals were of the highest grade available.

#### In vivo AICAR treatment and plasma analyses

Male albino rats (Wistar strain) weighing 150–200 g were maintained on a 12/12 h light/dark cycle at 22°C and fed standard laboratory chow ad libitum. Rats were given a single daily intraperitoneal (i.p.) injection of either saline or AICAR [0.7g/kg body weight (b.w.)] for 4 and 8 weeks. The dosage was chosen based on previous in vivo rat studies that used between 0.5 and 1.0g/kg b.w. for chronic AICAR injections (7, 10, 11). Saline-injected rats were pair-fed to the AICAR-treated group to control for effects of altered food intake induced by the treatment. Control animals were pair-fed according to the average amount of chow consumed by the AICAR-treated animals the previous day. Pair-fed animals received one-third of the total food in the morning (09:00) and the remaining two-thirds immediately prior to lights off at 19:00 to avoid prolonged periods of fasting. Weekly blood samples were collected prior to daily injections from the saphenous vein and the plasma was frozen for later analyses of leptin.

#### Determination of in vivo metabolic parameters

The Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus Instruments, Inc., Columbus, OH) was used to perform all automated in vivo determinations as previously described (14). Briefly, the CLAMS measures oxygen consumption (VO2), carbon dioxide production (VCO2), and respiratory exchange ratio (RER). Each cage is also equipped with a system of infrared beams that detects animal movement in the X and Z axes. EE was calculated by multiplying the calorific value (CV = 3.815 + 1.232 × RER) by VO2. Measurements using the CLAMS were performed on a weekly basis throughout the 8 week period. Animals were placed in the CLAMS at 10:00 immediately following the daily saline or AICAR injections. The first hour of data collected in the CLAMS was discarded, because it is the time required for the rats to fully acclimatize to the cage environment (14). The rats were monitored for a 24 h period encompassing the light (10:00–19:00 and 07:00–10:00) and dark (19:00–07:00) cycles.

#### Assessment of the anorectic response to leptin

Rats received daily injections of either saline or AICAR (0.7 mg/kg b.w.) for 2 weeks. During this treatment period, control animals were pair-fed as described above. On the day of
the test, food was removed from the cages at 07:00 and the animals were injected at 09:00 with either saline (control) or AICAR. Rats were fasted until the onset of the dark cycle (19:00; 12 h fast). At this point, the animals were subdivided into four groups: control, leptin, AICAR, and AICAR plus leptin and then injected i.p. with either saline (control conditions) or recombinant rat leptin (5 mg/kg b.w.). We used this dosage of leptin because it has been previously demonstrated to induce a significant reduction in food intake 4 h postinjection in rats (15). In order to measure food intake, animals were placed in the CLAMS 15 min postleptin injection for 24 h with ad libitum access to food.

**Extraction of tissues and calculation of LBM**

Fat depots from subcutaneous-inguinal (ING), epididymal (EPI), and retroperitoneal (RP) regions were quickly removed and weighed prior to being processed for various metabolic assays. Weights of all tissues were normalized per 100g of body weight. Lean body mass (LBM) was calculated as carcass weight with all skin, viscera, and fat depots removed (14).

**Isolation of adipocytes and measurement of palmitate oxidation**

After the 4 and 8 week treatment periods, fat depots from ING, EPI, and RP regions were quickly removed and adipocytes were isolated from each tissue as previously described (7, 16). For palmitate oxidation, cells (5 × 10⁵) were incubated in Krebs Ringer Buffer with all skin, viscera, and fat depots removed (14). Weights of all tissues were normalized per 100g of body weight. Lean body mass (LBM) was calculated as carcass weight with all skin, viscera, and fat depots removed (14).

**Morphometric and ultrastructural analyses**

Rats were anesthetized and transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Subsequently, WAT depots were carefully dissected and postfixed by overnight immersion in the same fixative at 4°C. For light microscopy, tissues were washed in phosphate buffer and dehydrated using an acetone gradient and embedded in an embedding mixture (Philips; Eindhoven, The Netherlands). Mitochondrial and cytoplasmic areas were quantified as area of mitochondria occupying the area of cytoplasm. Mitochondrial density was determined as area of mitochondria occupying the area of cytoplasm.

**Determination of content and phosphorylation of proteins by Western blot**

Fat depots were extracted and immediately snap-frozen in liquid nitrogen. Immediately after decapitation, the hypothalamus was dissected using the optic tracts, the thalamus, and the mammillary body as landmarks, and then quickly frozen in liquid nitrogen and stored at −80°C. The tissues were homogenized in a buffer containing 25 mM Tris-HCl and 25 mM NaCl (pH 7.4), 1 mM MgCl₂, 2.7 mM KCl, 1% Triton-X, and protease and phosphatase inhibitors (0.5 mM Na₃VO₄, 1 mM NaF, 1 μM leupeptin, 1 μM pepstatin, and 20 μM PMSF). Homogenates were centrifuged, the infranatant collected, and an aliquot was used to measure protein by the Bradford method. Samples were diluted 1:1 (v/v) with 2× Laemml sample buffer, heated to 95°C for 5 min, and subjected to SDS-PAGE. All primary antibodies were used in a dilution of 1:1,000 except for phospho-AMPK (1:500). Equal loading was confirmed by both β-actin detection and Coomassie blue staining of gels.

**RESULTS**

**Food intake, body weight, fat mass, and adipocyte morphology**

A reduction in food intake with AICAR injections has been observed in previous studies in rodents (18); therefore, food intake was measured on a daily basis in order to pair-feed control rats. Compared with ad libitum-fed rats, food intake was reduced by 10% and 3% after 4 and 8 weeks, respectively, in AICAR-treated rats. No differences in body weight or LBM were detected between control and AICAR-treated animals at any time point (data not shown).

![Fig. 1. Fat pad mass of inguinal, retroperitoneal, and epididymal depots after 4 and 8 weeks of AICAR treatment (panels A–C and D–F, respectively). Fat pad mass was normalized to 100 g of total body weight of the animal at the time of tissue harvest. N=3–4 per group. *P<0.05 versus control (Con). Data are expressed as mean ± SEM. Data are expressed as mean ± SEM.](http://www.jlr.org/content/suppl/2011/07/07/jlr.M015354.DC1.html)
Chronic AMPK activation reduces adiposity

Analyses of WAT mass indicated that ING, RP, and EPI fat depots were reduced in AICAR-treated animals by 39%, 56%, and 43% after 4 weeks and by 22%, 47%, and 34% after 8 weeks, respectively (Fig. 1). In ING and RP fat depots, adipocyte area was reduced by 33% and 37% at week 4 and by 37% and 42% at week 8, respectively (Fig. 2A–C). Adipocyte area was unchanged in EPI fat pads after 4 weeks of AICAR treatment but was 33% lower than controls after 8 weeks (Fig. 2B). Western blot analyses of UCP-1 protein content (Fig. 2D) and immunohistochemistry in WAT depots (data not shown) indicated that AICAR treatment did not increase the prevalence of brown adipocytes within the WAT depots.

Mitochondrial density and morphology

For assessment of mitochondrial density and ultrastructural changes, we analyzed ING and RP fat pads as representative depots for SC and VC WAT, respectively. After 4 and 8 weeks of AICAR treatment, mitochondrial density in both ING and RP WAT was increased by 1.78-fold and 2.45-fold and by 2.28-fold and 1.83-fold, respectively (Fig. 3A–D). Additionally, electron microscopy analysis revealed that adipocytes from rats treated with AICAR for 4 or 8 weeks had mitochondria with more defined cristae when compared with adipocytes from control animals (Fig. 3A–D, insets).

Effects of AICAR on AMPK and ACC phosphorylation and palmitate oxidation

As expected, AMPK phosphorylation (Thr172) increased in ING, RP, and EPI fat depots after 4 and 8 weeks of AICAR treatment. The most pronounced increase in AMPK phosphorylation was in the ING fat pads (Fig. 4A).

AMPK content in all fat depots was reduced in the AICAR group at week 4, an effect no longer present at week 8. ACC phosphorylation and protein content were markedly reduced at week 4 in ING, RP, and EPI fat pads; however the suppressive effect of AICAR on this variable was reversed at the 8 week time point with increased ACC content (Fig. 4A). Palmitate oxidation increased in ING and RP adipocytes by \( \frac{1}{4} \)-fold and 1.84-fold, respectively, after 4 weeks of AICAR treatment, with no change observed in EPI cells (Fig. 4B–D). Conversely, after 8 weeks of AICAR treatment, intra-adipocyte palmitate oxidation reduced by 40%, 53%, and 48% in ING, RP, and EPI adipocytes, respectively (Fig. 4E–G). Quantification of all WAT blots...
from 4 and 8 week animals are available in supplementary Figs. I and II, respectively.

**Whole-body EE, spontaneous ambulatory activity, and RER**

Baseline values were collected prior to commencing the study and no differences existed between the two groups with respect to EE and ambulatory activity (data not shown). Time-course analysis revealed that EE increased by 8% at week 4 and then by 16% at week 8 during the dark cycle in AICAR-treated rats (Fig. 5A, B). This was also accompanied by 29 and 33% increases in dark cycle ambulatory activity as compared with controls in weeks 4 and 8, respectively (Fig. 5C, D). RER was lower during the first light cycle (11:00 to 19:00) in AICAR-treated versus control rats (0.928 ± 0.007 vs. 0.902 ± 0.011 and 0.925 ± 0.005 vs. 0.894 ± 0.015) ~8 h subsequent to AICAR injection after 4 (Fig. 6A, B) and 8 weeks (Fig. 6C, D) respectively, indicating a shift toward fat oxidation in AICAR-treated animals. No differences in RER were detected between control and AICAR-treated rats during the dark cycle. However, during the second light cycle that preceded the daily AICAR injection (07:00 to 10:00), RER was lower in control than AICAR-treated animals (0.937 ± 0.005 vs. 0.997 ± 0.002 and 0.949 ± 0.002 vs. 0.979 ± 0.003) after 4 and 8 weeks, respectively (Fig. 6). This resulted from the pair-feeding procedure in which the control animals consumed their allotment of food before the end of the dark cycle leading to a reduction in RER.

**Effects of AICAR on plasma measurements and hypothalamic leptin signaling**

At weeks 4 and 8 of treatment, plasma leptin in AICAR-injected animals was lower than controls by 42% and 48%, respectively (Fig. 7A). In the hypothalamus, STAT3 phosphorylation at tyrosine 705 was either unchanged or increased and AMPK phosphorylation was consistently reduced after 4 and 8 weeks of AICAR treatment, although the content of these proteins remained unchanged (Fig. 7B). Hypothalamic SOCS3 content was also markedly

---

**Fig. 3.** Mitochondrial density and morphology in inguinal (A, C) and retroperitoneal (B, D) fat depots at 4 and 8 weeks. Lipid droplet (LD). Arrows point to cristae within mitochondria (inset). All images were taken at 12,500× magnification and insets are magnified. Scale bar represents 2 μm and applies to all panels. N=3 per group. Unpaired t-tests. *P<0.05 versus control (Con). Data are expressed as mean ± SEM.
Chronic AMPK activation reduces adiposity

adipocytes, indicating that not all VC fat depots change their metabolic profile in response to chronic AMPK activation. Our observations are in line with previous reports that EPI fat is more “resistant” to morphological and metabolic changes compared with ING and RP fat depots, which have greater plasticity and ability to change metabolic function upon stimulation (12). Interestingly, although AICAR treatment reduced food intake and increased EE, these animals still gained fat mass between the 4 and 8 week period similar to control animals. From an energy balance perspective, this could be due to the attenuated anorectic effect of AICAR at the 8 week time point (3% reduction in food intake) compared with 4 weeks (10% reduction in food intake). Additionally, the suppression of intra-adipocyte oxidation observed at 8 weeks would also prevent depletion of lipid content from the WAT. Therefore, the increase in EE must have been counteracted by the above factors and could help explain why AICAR-treated animals still gained fat mass between the 4 and 8 week time period.

A surprising finding of this study was that the ability of adipocytes to oxidize FAs was increased and reduced after 4 and 8 weeks of AICAR treatment, respectively. This occurred despite the fact that mitochondrial density was augmented at both time points, indicating that the activity of the oxidative machinery was regulated differently during the course of treatment. The precise mechanisms underlying these differences are not clear. It may be at least partially explained by the fact that the initial adaptive responses to AMPK activation in WAT were driven to shift toward oxidation of FAs. This is supported by our previous findings that chronic AICAR-induced AMPK activation promotes alterations in adipose tissue metabolism that leads to reduced VC and SC adiposity in rats. These effects were characterized by increased mitochondrial density and by the presence of mitochondria with more defined cristae in the WAT of AICAR-treated animals. This was also accompanied by time-dependent upregulation of FA oxidation in ING and RP but not in EPI adipocytes, indicating that not all VC fat depots change their metabolic profile in response to chronic AMPK activation. Our observations are in line with previous reports that EPI fat is more “resistant” to morphological and metabolic changes compared with ING and RP fat depots, which have greater plasticity and ability to change metabolic function upon stimulation (12). Interestingly, although AICAR treatment reduced food intake and increased EE, these animals still gained fat mass between the 4 and 8 week period similar to control animals. From an energy balance perspective, this could be due to the attenuated anorectic effect of AICAR at the 8 week time point (3% reduction in food intake) compared with 4 weeks (10% reduction in food intake). Additionally, the suppression of intra-adipocyte oxidation observed at 8 weeks would also prevent depletion of lipid content from the WAT. Therefore, the increase in EE must have been counteracted by the above factors and could help explain why AICAR-treated animals still gained fat mass between the 4 and 8 week time period.

**DISCUSSION**

Here, we report novel findings that chronic AICAR-induced AMPK activation promotes alterations in adipose tissue metabolism that leads to reduced VC and SC adiposity in rats. These effects were characterized by increased mitochondrial density and by the presence of mitochondria with more defined cristae in the WAT of AICAR-treated animals. This was also accompanied by time-dependent upregulation of FA oxidation in ING and RP but not in EPI
been demonstrated in 3T3-L1 adipocytes that the content and/or activity of ACC are decreased in cells treated with various AMPK agonists, along with other adipogenic markers required for differentiation of preadipocytes into mature fat cells (4, 5). In our study, animals begin AICAR treatment at ~6 to 7 weeks in age, which may have affected adipogenesis in preadipocytes present in the WAT. Interestingly, at 8 weeks, there was a rebound in ACC protein content with AICAR treatment although phosphorylation of this enzyme still remained suppressed in all fat depots. It is possible that the reemergence of ACC after 8 weeks of treatment was part of the adaptive metabolic response involved in the time-dependent downregulation of FA oxidation under conditions of reduced adiposity. Importantly, we also observed that ACC phosphorylation was not induced despite marked increases in AMPK phosphorylation at week 8 of AICAR treatment. This suggests that AMPK-independent mechanisms regulated ACC activity as adipocyte lipid content reduced with AICAR treatment. Work in our laboratory with adipocytes has demonstrated that certain metabolic effects of AICAR in WAT, such as FA oxidation and glucose uptake, are indeed mediated by AMPK (21, 22). However, because our treatment is in vivo and delivered systemically, we must acknowledge that AMPK-independent effects may be taking place resulting in changes to parameters affecting whole-body metabolism.

Our immunohistochemistry (data not shown) and Western blot analyses for the presence of UCP-1 in VC and SC fat depot demonstrated that brown adipogenesis by either transdifferentiation of white into brown adipocytes or recruitment of brown adipocyte precursors present within WAT was not induced with chronic AICAR-induced AMPK activation. Moreover, histological analysis excluded the development of UCP-1 negative multilocular adipocytes. Considering that AMPK is activated under conditions of ATP depletion and acts to restore intracellular energy levels (3), it is compatible that UCP-1 content and activity was not upregulated. This would allow substrate oxidation to be diverted toward ATP synthesis instead of nonshivering thermogenesis, ultimately serving to restore cellular energy levels. Therefore, our data provide evidence that the increased oxidative machinery of adipocytes exposed to chronic AICAR-induced AMPK activation did not result from white adipocytes converting to brown adipocytes. The absence of AMPK-induced BAT within WAT depots in our study is at odds with recent studies that have demonstrated this effect in mice exposed to chronic AICAR treatment (18). Species differences (mice vs. rats), duration of AICAR treatment (2 weeks vs. 4 and 8 weeks), dosage (0.5 mg/g b.w. vs. 0.7 mg/g b.w.) and frequency of injections (3 vs. 7 days a week) could explain the different responses to chronic AICAR treatment between these studies.

The observed elevation in whole-body EE after 4 (8%) and 8 weeks (16%) of AICAR treatment seems to be driven mainly by increased dark cycle locomotor activity. In fact, this variable was significantly increased by 29% and 33% after 4 and 8 weeks of AICAR treatment, respectively, which is in line with studies where AICAR-injected mice elicited enhanced exercise capacity (10). Increased substrate
oxidation by itself in skeletal muscle and liver did not seem to have contributed to increased EE in AICAR-treated rats. This is based on the fact that EE was only increased in AICAR-treated rats during the dark cycle when RER data indicated that there was no difference in substrate oxidation between the pair-fed controls and AICAR-treated rats. Importantly, others have also shown that the increases in mitochondrial FA oxidation do not necessarily lead to elevated whole-body EE (2).

It has been demonstrated repeatedly in rodents and humans that a reduction in fat mass is almost invariably followed by activation of energy-sparing mechanisms, which causes resistance to continuous long-term reduction in adiposity (13, 23, 24). At the whole-body level, these energy-sparing mechanisms could counteract and offset potential fat-reducing effects induced by remodeling white adipocyte metabolism toward a more oxidative phenotype. The activation of energy-sparing mechanisms under conditions of reduced adiposity has been attributed to a drop in circulating leptin because exogenous replacement of this hormone to preweight-loss values reverses this adaptive response (24). In order to exert its effects on energy balance (25), leptin must bind to its receptor (LepR), permitting STAT3 to dock onto the LepR. STAT3 is then phosphorylated, homodimerizes, and enters the nucleus to promote the expression of genes that inhibit food intake and increase EE. It also promotes the expression of SOCS3, which serves as a negative feedback regulator of leptin signaling. Therefore, although activation of AMPK in the hypothalamus induces food intake and favors weight gain, inhibition of this kinase by leptin blocks these centrally-mediated effects on energy balance (26, 27). Based on these observations, we hypothesized that energy-sparing mechanisms would be activated in AICAR-treated rats. This could occur by AICAR directly increasing hypothalamic AMPK activity, as previous studies have demonstrated that this drug can cross the blood-brain barrier with limited permeability (28). Alternatively, AICAR could indirectly lead to activation of energy-sparing mechanisms by reducing circulating leptin as a consequence of fat loss induced by prolonged AMPK activation in SC and VC fat depots. Time-course analyses revealed that circulating leptin indeed dropped ~40% in AICAR-treated rats when compared with pair-fed controls, which was compatible with the differences in adiposity between the groups. However, phosphorylation of hypothalamic AMPK was reduced, whereas STAT3 phosphorylation was either the same or increased in AICAR-injected animals when compared with controls after 4 and 8 weeks. Furthermore, these effects were accompanied by marked reductions in the content of SOCS3 in the hypothalamus. These findings indicated that leptin sensitivity in this tissue was actually increased with systemic AICAR-induced AMPK activation. In line with this hypothesis, our data suggest...
Based on our data, this approach causes neither WAT transdifferentiation nor recruitment of brown adipocyte precursors within WAT. Rather, it increases the oxidative machinery in white adipocytes and induces remodeling of WAT metabolism toward a catabolic state. Importantly, the adipose-reducing effects of chronic AICAR-induced AMPK activation increased hypothalamic leptin sensitivity, and thus did not trigger the typical centrally-mediated adaptive responses that oppose long-term weight loss.

that with respect to the anorectic effects of leptin, AICAR-treated animals showed a greater sensitivity to this hormone compared with their control counterparts. This is corroborated by our hypothalamic signaling data indicating that P-AMPK was reduced in AICAR-treated rats. Interestingly, leptin has been demonstrated to play a major role in relaying to the hypothalamus information regarding the amount of energy stored in the organism, allowing the central nervous system to regulate nonexercise activity thermogenesis accordingly (23, 29, 30). Therefore, the increase in ambulatory activity and EE observed in this study could also be attributed to enhanced central nervous system leptin sensitivity. Further studies are required to investigate possible direct actions of AICAR on specific hypothalamic sites involved in the control of food intake and energy homeostasis.

Altogether, our novel findings provide evidence that significant reductions in adiposity may be achieved through systemic pharmacological AMPK activation. Based on our data, this approach causes neither WAT to

### TABLE 1. Food intake in control and AICAR-treated rats injected without or with leptin

<table>
<thead>
<tr>
<th>Food intake (g/24 h)</th>
<th>Food intake (g/4 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saline</strong></td>
<td><strong>Leptin</strong></td>
</tr>
<tr>
<td>Control</td>
<td>12.50 ± 1.54</td>
</tr>
<tr>
<td></td>
<td>8.19 ± 1.28&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>AICAR</td>
<td>8.74 ± 0.20&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>6.76 ± 0.34&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>P < 0.05 compared with control-saline.

<sup>b</sup>P < 0.05 compared with control-leptin.

<sup>c</sup>P < 0.05 compared with control-saline and AICAR-saline conditions.

Animals were injected on a daily basis with either saline (vehicle) or AICAR (0.7 mg/kg b.w.) for 2 weeks. Subsequently, rats were fasted for 12 h prior to injection with either saline or leptin and refed ad libitum. Food intake was monitored 4 and 24 h postleptin injection as a measure of sensitivity to the anorectic effects of leptin. N = 4 for each condition. Data expressed as mean ± SEM.

The authors thank Cristina Maria Zingaretti from the University of Ancona for her technical expertise in acquiring transmission electron microscope images.

### REFERENCES


